Key Takeaways WST's Q3 EPS of $1.96 beat estimates by 17.4%, with revenues up 7.7% year over year.WST's Proprietary Products sales rose 7.7%, driven by 16.3% growth in High-Value Product components.WST lifted full-year EPS view to $7.06-$7.11, citing demand strength and FX-related benefits.West Pharmaceutical Services, Inc. (WST) delivered adjusted third-quarter 2025 earnings per share (EPS) of $1.96, which moved up 5.9% year over year. The figure topped the Zacks Consensus Estimate by 17.4%.The adjustments ...